Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy of Fish Oil in Lupus Patients

This study has been completed.
Information provided by (Responsible Party):
Michelle Petri M.D.,MPH, Johns Hopkins University Identifier:
First received: January 22, 2009
Last updated: June 26, 2012
Last verified: June 2012
The investigators hypothesize that low-dose dietary supplementation with omega-3 fish oil will improve disease activity and endothelial function in Systemic Lupus Erythematosus (SLE) patients.

Condition Intervention Phase
Systemic Lupus Erythematosus
Drug: Omega-3-acid ethyl esters
Device: flow-mediated dilation of the brachial artery
Drug: Fish oil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • We will compare omega-3 versus placebo to determine the effect on brachial artery flow dilation. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • We will determine the effect of omega-3 versus placebo on disease activity in SLE. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • We will compare omega-3 versus placebo to determine the effect on markers of inflammation: IL-6, ICAM and VCAM. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 106
Study Start Date: February 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
fish oil
Drug: Omega-3-acid ethyl esters
Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
Other Name: Lovaza
Device: flow-mediated dilation of the brachial artery
flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
Placebo Comparator: 2 Device: flow-mediated dilation of the brachial artery
flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
Drug: Fish oil
3 capsules qd for 12weeks

Detailed Description:
Patients with SLE have a fifty-fold increased risk of myocardial infarction. This risk is not totally explained by traditional cardiovascular risk factors. In a previous double-blind study of atorvastatin in SLE, there was no reduction in surrogate measures of coronary artery disease (coronary calcium, coronary IMT, carotid plaque) and no effect on inflammatory markers such as ICAM, VCAM, IL-6 and CRP. We need to find novel approaches to reduce coronary artery disease in SLE. In a preliminary study, omega-3 was shown to improve flow mediated dilation of the brachial artery, oxidative stress and disease activity in lupus patients. In this study we will determine if omega-3 improves brachial artery flow dilation, disease activity and other vascular inflammatory markers (IL-6, s-VCAM-1, s-ICAM-1) in SLE, in a double-blind placebo-controlled trial.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a clinical diagnosis of SLE are eligible.
  • Patients must be 18 years of age or older and able to give informed consent.

Exclusion Criteria:

  • SLE patients who are allergic to fish oil or any omega 3 product.
  • Patients who are pregnant or are planning to become pregnant or are nursing.
  • Omega-3 use within the previous 6 weeks of enrollment.
  • Use of warfarin or heparin.
  • Patients who have coronary artery disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00828178

United States, Maryland
Lupus Center, Johns Hopkins University
Baltimore, Maryland, United States, 21205
The Johns Hopkins Lupus Center
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Michelle Petri M.D.,MPH
Principal Investigator: Michelle A Petri, MD, MPH Johns Hopkins University
  More Information

Responsible Party: Michelle Petri M.D.,MPH, Principal investigator, Johns Hopkins University Identifier: NCT00828178     History of Changes
Other Study ID Numbers: NA_00023813 
Study First Received: January 22, 2009
Last Updated: June 26, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on October 21, 2016